Publications by authors named "W L Donnellan"

People with dementia and carers can face many barriers, or inequalities, in accessing a diagnosis or care. These barriers are unjust and can be addressed by the right interventions, to ensure that everyone receives equitable access to diagnosis and care. A lack of knowledge about dementia in the health and social care workforce is a recognised barrier.

View Article and Find Full Text PDF

The treatment setting influences acute myeloid leukemia (AML) outcomes. Most cancer patients receive care in the community, yet few studies have evaluated the effectiveness of clinical programs outside of academic or National Cancer Institute (NCI)-designated cancer centers. This was a multi-level, case-controlled study of real-world outcomes for initial AML treatment in a community-based network for 1,391 patients with AML between 2011 and 2018.

View Article and Find Full Text PDF

Venetoclax, a highly selective BCL-2 inhibitor, combined with hypomethylating agents (HMAs) azacitidine or decitabine, is approved for the treatment of newly diagnosed acute myeloid leukemia (ND AML) in patients who are ineligible to receive intensive chemotherapy. Previous clinical studies initiated venetoclax plus HMA in an inpatient setting owing to concerns of tumor lysis syndrome (TLS). This study (NCT03941964) evaluated the efficacy and safety of venetoclax plus HMA in a United States community-based outpatient setting in patients with ND AML (N = 60) who were treatment naïve for AML, ineligible to receive intensive chemotherapy, had no evidence of spontaneous TLS at screening, and were deemed as appropriate candidates for outpatient initiation of venetoclax plus HMA by the investigator.

View Article and Find Full Text PDF
Article Synopsis
  • The study focused on a bispecific antibody, JNJ-67571244, in patients with relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), aiming to identify maximum tolerated dose and safety outcomes.
  • The phase I trial, involving 68 patients, encountered significant side effects and toxicity, with 88.2% showing treatment-emergent adverse events, while no substantial clinical responses were observed.
  • The prolonged treatment strategy intended to enhance tolerability did not prevent adverse effects, and the study was terminated without achieving the planned exposure levels for determining effective dosing.
View Article and Find Full Text PDF

The aim of this study was to explore unpaid carers' experiences of supporting people with dementia to use social media. Unpaid carers ( = 234) responded to an online survey about their attitudes towards people with dementia using social media and any experiences supporting this usage. Responses to closed questions were analysed using frequency analysis; qualitative data were analysed thematically.

View Article and Find Full Text PDF